Ann Boriack-Sjodin

Company: Takeda Pharmaceutical

Job title: Executive Director & Global Head of Structural Biology

 

Seminars:

Panel Discussion: Exploring Future Directions in Structure-Based Drug Design 4:00 pm

  • What are the emerging trends in structure-based drug design that hold the most promise for advancing therapeutics across different modalities?
  • How can the integration of various structural biology techniques unlock new opportunities for multi-modal therapeutic approaches?
  • What areas of structural biology require greater focus or investment to accelerate progress and benefit multiple therapeutic modalities?
  • Looking ahead: What are the key scientific or technological breakthroughs we can expect in the next 5-10 years that will transform structure-based drug design?

day: Day 2

Ann Boriask sJODIN